Skip Navigation



NDT Advance Access published online on August 9, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh728
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/10/2120    most recent
gfh728v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Salcedo-Alejos, M.
Right arrow Articles by Guerrero-Romero, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salcedo-Alejos, M.
Right arrow Articles by Guerrero-Romero, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received May 18, 2004
Accepted December 1, 2004

Original Articles

Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial

Mario Salcedo-Alejos 1, Felipe Banda-Espinoza 2, Martha Rodríguez-Morán 3, and Fernando Guerrero-Romero 3*

1 Nephrology Department, General Hospital, Mexican Social Security Institute, Torreón, Coah
2 Pediatric Endocrinology Department, General Hospital, Mexican Social Security Institute, Torreón, Coah
3 Medical Research Unit in Clinical Epidemiology, Mexican Social Security Institute, Durango, Mexico; Research Group on Diabetes and Chronic Illnesses, Durango, Mexico

* To whom correspondence should be addressed.
Fernando Guerrero-Romero, E-mail: guerrero_romero{at}hotmail.com



  Abstract

Background. Previous studies in type 2 diabetes have demonstrated the renoprotective effect of AT1-receptor antagonist drugs, but data on type 1 diabetic (T1DM) children are scarce. The aim of this study was to evaluate the effectiveness of the AT1-receptor antagonist irbesartan in reducing creatinine clearance rate (CCR) in non-hypertensive T1DM children with renal hyperfunction.

Methods. In this randomized, double-blind, placebo-controlled trial we enrolled 20 T1DM children aged 6-16 years and randomly allocated them to receive either irbesartan (1 mg/kg body weight) or placebo daily for 12 weeks. Children were eligible to participate if they had renal hyperfunction, defined as a CCR >20 ml/min/1.73 m2 body surface area. In addition, the participants could not have high blood pressure or renal failure and they could not be receiving diuretics or angiotensin-converting enzyme inhibitors. The primary endpoint of the trial was the change in CCR.

Results. There were no significant differences in age, duration of diabetes or body mass index between the two groups. No subject dropped out, withdrew consent or had side effects or adverse events attributable to irbesartan or the placebo. In the irbesartan group, CCR decreased from 155.0±6.6 to 86.2±7.4 ml/min (P<0.0001); CCR did not change significantly in the control group (154.1±13.1 to 172.0±15.5 ml/min; P = 0.86). Blood pressures at baseline and throughout the study were similar in both groups.

Conclusions. Irbesartan significantly reduces CCR in non-hypertensive, non-controlled T1DM children; the clinical significance of this finding, however, remains to be established.

Keywords: acute renal hypertrophy-hyperfunction; AT1-receptor antagonist; children; creatinine clearance; irbesartan; type 1 diabetes.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. M Franks, C. E O'Brien, C. D Stowe, T. G Wells, and S. F Gardner
Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children
Ann. Pharmacother., October 1, 2008; 42(10): 1388 - 1395.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.